Skip to main content

KSL Biomedical to Commercialize PredictImmune IBD Test in North America

NEW YORK – Immune prognostic tools developer PredictImmune announced on Tuesday an exclusive commercial partnership with KSL Biomedical for KSL to commercialize PredictImmune's PredictSURE inflammatory bowel disease test throughout North America.

The IBD test, which was commercialized in the United Kingdom and Ireland earlier this year, is expected to be available in North America in the first quarter of 2020. Under the agreement, Buffalo, New York-based KSL will commercialize and facilitate the fulfillment of orders of the test, and receive and process the samples through its testing laboratory, KSL Diagnostics.

The blood-based biomarker test, which leverages quantitative PCR technology, is meant to guide treatment options for people with IBD by differentiating whether the disease will likely be aggressive or milder, PredictImmune said in a statement. The North American launch marks Cambridge, UK-based PredictImmune's first product launch outside the UK.

"KSL has a very clear focus on the auto immune sector and a willingness to support and invest in our drive and expansion into North America, which is a key market for us," said PredictImmune's CEO Paul Kinnon. "This agreement facilitates an increased focus on patient health and wellness that is core to our commercialization strategy."